Canada markets close in 6 hours 26 minutes
  • S&P/TSX

    19,665.85
    -3.32 (-0.02%)
     
  • S&P 500

    4,130.34
    -9.72 (-0.23%)
     
  • DOW

    32,840.62
    +8.08 (+0.02%)
     
  • CAD/USD

    0.7775
    -0.0001 (-0.02%)
     
  • CRUDE OIL

    91.70
    +0.94 (+1.04%)
     
  • BTC-CAD

    29,983.73
    -1,128.46 (-3.63%)
     
  • CMC Crypto 200

    541.57
    -15.78 (-2.83%)
     
  • GOLD FUTURES

    1,813.90
    +8.70 (+0.48%)
     
  • RUSSELL 2000

    1,941.21
    +19.39 (+1.01%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • NASDAQ

    12,528.70
    -115.76 (-0.92%)
     
  • VOLATILITY

    21.91
    +0.76 (+3.59%)
     
  • FTSE

    7,488.46
    +6.09 (+0.08%)
     
  • NIKKEI 225

    27,999.96
    -249.28 (-0.88%)
     
  • CAD/EUR

    0.7586
    -0.0040 (-0.52%)
     

Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So should Aprea Therapeutics (NASDAQ:APRE) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for Aprea Therapeutics

Does Aprea Therapeutics Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at September 2021, Aprea Therapeutics had cash of US$61m and no debt. Looking at the last year, the company burnt through US$41m. That means it had a cash runway of around 18 months as of September 2021. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Aprea Therapeutics' Cash Burn Changing Over Time?

Aprea Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With cash burn dropping by 6.1% it seems management feel the company is spending enough to advance its business plans at an appropriate pace. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can Aprea Therapeutics Raise More Cash Easily?

While Aprea Therapeutics is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Aprea Therapeutics' cash burn of US$41m is about 110% of its US$37m market capitalisation. That suggests the company may have some funding difficulties, and we'd be very wary of the stock.

Is Aprea Therapeutics' Cash Burn A Worry?

On this analysis of Aprea Therapeutics' cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried. Summing up, we think the Aprea Therapeutics' cash burn is a risk, based on the factors we mentioned in this article. On another note, Aprea Therapeutics has 4 warning signs (and 1 which is concerning) we think you should know about.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting